These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 31968344)

  • 1. Vaccination in Patients with Inflammatory Bowel Diseases.
    Manser CN; Maillard MH; Rogler G; Schreiner P; Rieder F; Bühler S;
    Digestion; 2020; 101 Suppl 1(Suppl 1):58-68. PubMed ID: 31968344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic drugs for inflammatory bowel disease.
    Yanai S; Matsumoto T
    Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.
    Gisbert JP; Chaparro M
    Drugs; 2020 Jul; 80(11):1085-1100. PubMed ID: 32562207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of infection in elderly patients with inflammatory bowel disease under biologics: A prospective, multicenter, observational, one-year follow-up comparative study.
    Bozon A; Nancey S; Serrero M; Caillo L; Gilletta C; Benezech A; Combes R; Danan G; Akouete S; Pages L; Bourgaux JF; Le Cosquer G; Boivineau L; Meszaros M; Altwegg R
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102107. PubMed ID: 36906225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccinating the inflammatory bowel disease patient.
    Desalermos AP; Farraye FA; Wasan SK
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):91-102. PubMed ID: 25160668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on vaccinating the inflammatory bowel disease patient.
    Zullow S; Farraye FA
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):229-239. PubMed ID: 30791761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West.
    Kochar B; Herfarth HH
    Inflamm Intest Dis; 2018 Nov; 3(1):11-15. PubMed ID: 30505837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.
    Chang S; Hudesman D
    Curr Gastroenterol Rep; 2020 Jan; 22(2):7. PubMed ID: 32002688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombosis in IBD in the Era of JAK Inhibition.
    Solitano V; Fiorino G; D'Amico F; Peyrin-Biroulet L; Danese S
    Curr Drug Targets; 2021; 22(1):126-136. PubMed ID: 32881668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
    Conrad MA; Kelsen JR
    Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Emerging Therapies: What Are Promising in the Near Future?].
    Seo GS; Lee SH
    Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease.
    Walsh AJ; Weltman M; Burger D; Vivekanandarajah S; Connor S; Howlett M; Radford-Smith G; Selby W; Veillard AS; Grimm MC; Travis SP; Lawrance IC
    J Crohns Colitis; 2013 Nov; 7(10):e449-56. PubMed ID: 23601754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update.
    Borman ZA; Côté-Daigneault J; Colombel JF
    Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1101-1108. PubMed ID: 30277409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing Risks with Biologics.
    Click B; Regueiro M
    Curr Gastroenterol Rep; 2019 Jan; 21(2):1. PubMed ID: 30635807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Table: safety of drugs for IBD in pregnancy.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.